Stockscreener 앱 받기
51.29
0.73%
0.37
시간 외 거래:
51.29
전일 마감가:
$50.92
열려 있는:
$51.15
하루 거래량:
1.23M
Relative Volume:
1.19
시가총액:
$4.09B
수익:
$541.74M
순이익/손실:
$88.01M
주가수익비율:
47.22
EPS:
1.0862
순현금흐름:
$155.34M
1주 성능:
+6.48%
1개월 성능:
+33.29%
6개월 성능:
+21.51%
1년 성능:
+91.67%
1일 변동 폭
$50.50
$52.76
1주일 범위
$46.04
$52.76
52주 변동 폭
$22.61
$52.76
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
51.29 | 3.92B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
461.69 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.76 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
546.09 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
124.33 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
357.00 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Jefferies | Buy |
| 2025-12-02 | 재개 | Morgan Stanley | Underweight |
| 2025-10-20 | 개시 | Canaccord Genuity | Hold |
| 2025-03-20 | 개시 | Craig Hallum | Buy |
| 2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-16 | 개시 | UBS | Buy |
| 2024-10-10 | 개시 | Guggenheim | Buy |
| 2024-02-23 | 재확인 | Needham | Buy |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-11-18 | 재개 | Goldman | Buy |
| 2021-06-15 | 개시 | Raymond James | Outperform |
| 2021-02-18 | 재개 | Needham | Buy |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 개시 | Morgan Stanley | Underweight |
| 2019-07-31 | 개시 | Lake Street | Buy |
| 2019-07-02 | 개시 | Needham | Buy |
| 2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 재개 | BTIG Research | Buy |
| 2016-11-14 | 재개 | Leerink Partners | Outperform |
| 2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-11 | 재확인 | Leerink Partners | Outperform |
| 2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
Veracyte (VCYT) director Jens Holstein awarded 5,272 restricted stock units - Stock Titan
Veracyte (VCYT) director Eliav Barr receives 5,272 restricted stock units - Stock Titan
Director at Veracyte (VCYT) receives grant of 5,272 restricted stock units - Stock Titan
Evan Jones of Veracyte (NASDAQ: VCYT) receives 5,272 restricted stock units - Stock Titan
Veracyte (VCYT) director Robert Epstein receives 5,272-share RSU grant - Stock Titan
Veracyte (VCYT) director awarded 5,272 RSUs vesting over one year - Stock Titan
Veracyte, Inc. 2023 Equity Incentive Plan Amended – SEC 8-K Filing Details and Company Information - Minichart
FMR LLC's Strategic Acquisition of Veracyte Inc Shares - GuruFocus
Veracyte (VCYT) investors back 3.5M-share equity plan increase and elect full board - Stock Titan
Veracyte (NASDAQ:VCYT) Hits New 12-Month HighHere's Why - MarketBeat
Why Veracyte (VCYT) is a top momentum stock for the long term - MSN
Here's why Veracyte (VCYT) is a strong growth stock - MSN
Veracyte Inc Annual Shareholders Meeting Transcript - GuruFocus
Here's how much a $1000 investment in Veracyte made 10 years ago would be worth today - MSN
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Veracyte, Inc. $VCYT Shares Sold by Amova Asset Management Americas Inc. - MarketBeat
Veracyte, Inc. $VCYT Shares Sold by GW&K Investment Management LLC - MarketBeat
Veracyte Inc (VCYT) Stock Down 3.0% but Still Overvalued -- GF S - GuruFocus
Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Why is Veracyte (VCYT) up 18.2% since last earnings report? - MSN
Veracyte (VCYT) Is Up 9.4% After New Phase III Data Validates Prosigna Chemotherapy-Guidance Role – Has The Bull Case Changed? - Sahm
FMR LLC holds 8.06M Veracyte (VCYT) shares, representing 10.1% - Stock Titan
Veracyte Insider Sold Shares Worth $6,919,585, According to a Recent SEC Filing - marketscreener.com
Veracyte EVP Annie McGuire sells $158k in company stock By Investing.com - Investing.com UK
Veracyte CFO Rebecca Chambers sells $177,082 in company stock By Investing.com - Investing.com Canada
Veracyte global chief commercial off sells $699,732 in stock By Investing.com - Investing.com South Africa
Veracyte CEO Marc Stapley sells $6.9m in company shares By Investing.com - Investing.com South Africa
Veracyte CFO Rebecca Chambers sells $177,082 in company stock - Investing.com
Veracyte (VCYT) CFO trades shares as RSUs vest and 10b5-1 plan executes - Stock Titan
Veracyte (VCYT) CAO reports 1,361 shares withheld for RSU tax obligations - Stock Titan
Veracyte global chief commercial off sells $699,732 in stock - Investing.com
Veracyte CEO Marc Stapley sells $6.9m in company shares - Investing.com
[144] VERACYTE, INC. SEC Filing - stocktitan.net
VCYT (NASDAQ) insider 10b5-1 sale of 10,204 shares; 3,176 RSUs registered - Stock Titan
VCYT Stock Price, Quote & Chart | VERACYTE INC (NASDAQ:VCYT) - ChartMill
How Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst Call - Yahoo Finance
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report? - Yahoo Finance
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate CancerSlideshow (NASDAQ:VCYT) 2026-06-03 - Seeking Alpha
Veracyte, Inc. (VCYT) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
Veracyte stock price target maintained at $42 by Canaccord on study results - Investing.com South Africa
Veracyte (VCYT) Launches Prosigna Breast Cancer Risk Test in the U.S. - GuruFocus
Wolfe Research initiates Veracyte stock coverage with Outperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates Veracyte stock coverage with Outperform rating - Investing.com
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Veracyte Inc 주식 (VCYT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Chambers Rebecca | Chief Financial Officer |
Jun 04 '26 |
Sale |
49.73 |
3,561 |
177,083 |
173,280 |
| Stapley Marc | Chief Executive Officer |
Jun 04 '26 |
Option Exercise |
36.60 |
138,051 |
5,052,667 |
578,545 |
| Stapley Marc | Chief Executive Officer |
Jun 04 '26 |
Sale |
50.12 |
138,051 |
6,919,585 |
440,494 |
| Leite John | Global Chief Commercial Off |
Jun 04 '26 |
Sale |
50.07 |
13,975 |
699,732 |
132,305 |
1.63%
2.88%
자본화:
|
볼륨(24시간):